IDRI appoints new CEO

H. Stewart Parker has been appointed as the new chief executive officer of the Infectious Disease Research Institute, a Seattle-based not-for-profit organization that applies innovative science to the research and development of products for infectious diseases of poverty.

"The board conducted an exhaustive international search as we sought the best candidate to lead IDRI," Franklyn Prendergast said. "Stewart's strength and status as a highly respected CEO made her a unique fit with IDRI's team, as well as with our core values and mission."

Parker is well-known in the biotechnology industry, having served as the CEO and president of Targeted Genetics Corp and as the former vice-president of corporate development at Immunex Corp.

"I look forward to working with Stewart, who represents a balance of entrepreneurial spirit and operational expertise," Steve Read, IDRI's founder and head of research and development, said.

Parker is currently a commercialization consultant with the Washington Biotechnology & Biomedical Association. She sits on multiple boards, including C3 Jian Inc. and OncoGenex.

"I couldn't be more thrilled to join IDRI," Parker said. "The organization possesses a number of technologies that may have an enormous impact on the health of the world. To support their innovation, IDRI possesses developmental capabilities that are rare in non-profits - yet urgently needed if global health funding is going to result in products that make a difference."

IDRI integrates capabilities like early stage drug discovery, manufacturing, clinical trials and preclinical testing to bring scientific innovation from the laboratory to people who need it the most.